These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 10755090)

  • 21. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention].
    Ceconi C; Mastrorilli F; Squasi PA; Gaitani S; Guardigli G; Ferrari R
    Ital Heart J; 2005 Nov; 6 Suppl 7():5S-13S. PubMed ID: 16485512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Further options with ramipril. Besides cardio- and nephro-protection diabetes prevention, too?].
    MMW Fortschr Med; 2003 Sep; 145(39):47. PubMed ID: 14649075
    [No Abstract]   [Full Text] [Related]  

  • 24. The HOPE study: comparison with other trials of secondary prevention.
    Otterstad JE; Sleight P
    Eur Heart J; 2001 Aug; 22(15):1307-10. PubMed ID: 11465962
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA; Molnar J; Arora RR
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospects for angiotensin receptor blockers in diabetic retinopathy.
    Sjølie AK
    Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S31-9. PubMed ID: 17321627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. More than just hype.
    Sigal RJ
    CMAJ; 2003 Jun; 168(13):1647; author reply 1647-8. PubMed ID: 12821615
    [No Abstract]   [Full Text] [Related]  

  • 30. Cardiovascular protection paradigms: is change on the horizon?
    Papademetriou V
    Rev Cardiovasc Med; 2007; 8(4):200-13. PubMed ID: 18192943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beta blockers and CVD protection: new frontiers.
    Pancholia AK; Jain V
    Indian Heart J; 2010; 62(2):99-100. PubMed ID: 21180297
    [No Abstract]   [Full Text] [Related]  

  • 32. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M
    Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
    Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The importance of managing cardiovascular risk in the treatment of hypertension: the role of ACE inhibitors and ARBs.
    Pierson CA; Epstein BJ; Roberts ME
    J Am Acad Nurse Pract; 2008 Nov; 20(11):529-38. PubMed ID: 19128336
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ
    Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implications from the Heart Outcomes Prevention Evaluation Study.
    Weir MR; Blantz RC
    Curr Opin Nephrol Hypertens; 2001 Jan; 10(1):61-3. PubMed ID: 11195053
    [No Abstract]   [Full Text] [Related]  

  • 39. ACE-inhibition for secondary prevention of cardiovascular events--should we change our recommendation after PEACE?
    Ferrari R
    Cardiovasc Drugs Ther; 2006 Feb; 20(1):11-2. PubMed ID: 16649066
    [No Abstract]   [Full Text] [Related]  

  • 40. Pragmatic and mechanistic trials.
    Califf RM; Woodlief LH
    Eur Heart J; 1997 Mar; 18(3):367-70. PubMed ID: 9076373
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.